Semaglutide

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost 15.7% of their body weight at 68 weeks, according to topline data from the REDEFINE 2 trial.

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the medication through a new Novo Nordisk direct-to-consumer program.

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since early 2022.

Adults with type 1 diabetes have greater reductions in body weight and HbA1c after using off-label semaglutide or tirzepatide than those not using either drug, according to data published in Diabetes Technology & Therapeutics.

ORLANDO — In this Healio Video Perspective from Telling It Like It Is, Jaclyn L. Kovach, MD, FASRS, overviews systemic therapies and retinal toxicity.

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk and the FDA announced.

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using semaglutide therapy than when they are not using the drug, according to findings from a retrospective study.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health issues, recent data suggest they may improve brain health.

Sodium-glucose cotransporter 2, or SGLT2, inhibitors may be more cardioprotective for older adults, whereas glucagon-like peptide-1 receptor agonists may confer greater HbA1c reductions in that population, according to a systematic review and meta-analysis.

Adults receiving semaglutide for the treatment of obesity were more likely to have antihypertensive or lipid-lowering therapy tapered or discontinued than those receiving placebo, according to data from the STEP trials.